Patched Homolog (PTCH1) Gene as a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation With Early Response to First-Line of Treatment Imatinib

被引：0
|
作者：
Rakha, Nahed Moawad [1 ]
Moahmed, Tamer [1 ]
Said, Rasha Magdy M. [1 ]
Ali, Esraa [1 ]
Abdulla, Nour Elhuda [1 ]
机构：
[1] Ain Shams Univ, Internal Med Dept, Clin Hematol Div, Fac Med, Cairo, Egypt
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; PTCH1; chronic phase; patched homolog gene; ELISA; imatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-024
引用
收藏
页码：S331 / S331
页数：1
相关论文
共 50 条
  • [21] Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia
    Lee, Sung-Eun
    Choi, Soo Young
    Oh, Yun Jeong
    Kim, Soo-Hyun
    Song, Hye-Young
    Yoo, Hea-Lyun
    Lee, Mi-Young
    Chae, Moon-Jung
    Kang, Ki-Hoon
    Hwang, Hee-Jeong
    Jang, Eun-Jung
    Kim, Dong-Wook
    LEUKEMIA RESEARCH, 2015, 39 (04) : 411 - 418
  • [22] Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
    Malhotra, Hemant
    Sharma, Pratibha
    Malhotra, Bharti
    Bhargava, Shipra
    Jasuja, Sandeep
    Kumar, Madhu
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 142 : 175 - 182
  • [23] Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line
    Dulucq, Stephanie
    Etienne, Gabriel
    Morisset, Stephane
    Klein, Emilie
    Chollet, Claudine
    Robbesyn, Fanny
    Turcq, Beatrice
    Tigaud, Isabelle
    Hayette, Sandrine
    Nicolini, Franck E.
    Mahon, Francois-Xavier
    ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1159 - 1168
  • [24] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Ganguly, Sandip
    Lakshmaiah, K. C.
    Jacob, Linu Abraham
    Babu, Suresh
    Dasappa, Lokanatha
    Babu, K. S. Govind
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 82 - 86
  • [25] Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia
    Baran, Yusuf
    Saydam, Guray
    JOURNAL OF BLOOD MEDICINE, 2012, 3 : 139 - 150
  • [26] Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges
    Breccia, Massimo
    Alimena, Giuliana
    CANCER LETTERS, 2012, 325 (01) : 18 - 25
  • [27] Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
    Osorio, S.
    Noblejas, A. Garcia
    Duran, A.
    Steegmann, J. L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) : 394 - 395
  • [28] Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia
    Cheng, Fang
    Cui, Zheng
    Li, Qiang
    Chen, Shi
    Li, Weiming
    Zhang, Yu
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 133
  • [29] Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia
    Jee Hyun Kong
    Yeung-Chul Mun
    Seonwoo Kim
    Hang Seok Choi
    Yeo-Kyeoung Kim
    Hyeoung-Joon Kim
    Joon Ho Moon
    Sang Kyun Sohn
    Sung-Hyun Kim
    Chul Won Jung
    Dong Hwan (Dennis) Kim
    International Journal of Hematology, 2012, 96 : 327 - 333
  • [30] Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia
    Kong, Jee Hyun
    Mun, Yeung-Chul
    Kim, Seonwoo
    Choi, Hang Seok
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Moon, Joon Ho
    Sohn, Sang Kyun
    Kim, Sung-Hyun
    Jung, Chul Won
    Kim, Dong Hwan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (03) : 327 - 333
12345